Vancouver BC, Canada (October 24, 2024) — Shackelford Pharma Inc. (“Shackelford” or the “Company”), a pharmaceutical company developing medicines for neurological diseases with significant unmet patient needs, is pleased to

Vancouver BC, Canada (February 6, 2023) — Shackelford Pharma Inc. (“Shackelford” or the “Company”), a pharmaceutical company developing medicines for neurological diseases with significant unmet patient needs, is pleased to

Shackelford Pharma congratulates O’Neill D’Cruz, a member of Shackelford’s clinical development team, and our Scientific Advisory Board Members Emilio Perucca and Jeffrey Buchhalter, co-authors of the article “EEG Parameters as

Shackelford Pharma Inc. Selected to Present at Life Science BC Invest in BC Vancouver BC, Canada (October 16, 2022) — Shackelford Pharma Inc., a pharmaceutical company developing medicines for neurological

Vancouver BC, Canada (October 16,2022) — Shackelford Pharma Inc. (“Shackelford” or the “Company”), a pharmaceutical company developing medicines for neurological diseases with significant unmet patient needs, is pleased to announce

SPI is a member of LifeSciences BC. LifeSciences BC is a non-profit, industry association which supports and represents the life science community of British Columbia through leadership, investment, advocacy and